Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 3/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE1A | P54750 | 3/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14896143 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL11096547 | 0.82 | KDM4E (0.45) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL22778205 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL22778178 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL29525638 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL9736640 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL14895908 | 0.80 | KDM4E (0.42) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL5420314 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL3739184 | 0.79 | CA2 (0.55) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL22778176 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304046-B2 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20040176332-A1 | Phosphoramide compounds | PURDUE RESEARCH FOUNDATION | 2004-09-09 | — | — | US | disclosed |
| US-6656926-B2 | For therapy and prophylaxis of cancer | PURDUE RESEARCH FOUNDATION | 2003-12-02 | — | — | US | disclosed |
| US-20030008850-A1 | For therapy and prophylaxis of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2001004130-A1 | PHOSPHORAMIDE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5229385-A | Thromboxane A2 and lipoxygenase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-20 | — | — | US | disclosed |
| US-5106858-A | For disfunction of heart, brain, lung or kidney | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0234729-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-4985447-A | USEFUL FOR TREATMENT AND PREVENTION OF DISEASES DUE TO DYSFUNCTION OF HEART, BRAIN, LUNG AND KIDNEY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4851413-A | TREATMENT OF HEART, BRAIN, LUNG OR KIDNEY DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176332-A1 | Phosphoramide compounds | RB1, RRM2B, RRM1 | KDM4E 3140/4885ALDH1A1 1067/4885MAPK1 1681/4885 |
| US-20030008850-A1 | For therapy and prophylaxis of cancer | BRCA1, RRM2B, FOLR1 | KDM4E 3105/4885ALDH1A1 27/4885MAPK1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.